Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch Health Companies Inc.BHC · Entity 4363 | President, Salix | August 19, 2019 | August 21, 2019 |
| Helix Acquisition Corp. IIIHLXC · Entity 6010 | Director | January 22, 2026 | January 23, 2026 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | January 07, 2026 | January 10, 2026 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch Health Companies Inc.
Report date August 19, 2019 · Filed August 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 20,756 |
Reported balance
After 2019-08-19 transaction · row 1
1 source rowRow 1 · 2019-08-19 · Sale · Disposed 10,773 · Balance 20,756 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.82 to $21.845 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range provided in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.82 to $21.845 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range provided in this footnote.
Helix Acquisition Corp. III
Report date January 22, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-01-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person owns 30,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-291933) and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person owns 30,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-291933) and have no expiration date.
NewAmsterdam Pharma Co N.V.
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,360 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 10,360 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07 | Direct | 15,300 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All the shares underlying the option will vest on January 2, 2027, the one-year anniversary of vesting start date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2: Each RSU was granted on January 7, 2026 for no consideration.
F3: All the shares underlying the option will vest on January 2, 2027, the one-year anniversary of vesting start date, subject to the Reporting Person's continued service through such date.
Spyre Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.51 · Expires 2036-05-27 | Direct | 8,026 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 8,026 · Balance 8,026 F1: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apogee Therapeutics, Inc.
Report date September 03, 2026 · Filed September 03, 2026
Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.60 · Expires 2033-08-17 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Disposition to issuer · Disposed 150,000 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.85 · Expires 2034-06-05 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Disposition to issuer · Disposed 10,370 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.66 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-03 · Disposition to issuer · Disposed 14,461 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.00 · Expires 2036-06-09 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-03 · Disposition to issuer · Disposed 7,657 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.
BridgeBio Oncology Therapeutics, Inc.
Report date August 11, 2025 · Filed August 11, 2025
Section 16 reporting ended · disclosed 2025-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2025-08-11 transaction · row 1
1 source rowRow 1 · 2025-08-11 · Exercise / conversion · Acquired 30,000 · Balance 30,000 F1: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. |
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-11 · Exercise / conversion · Disposed 30,000 · Balance 0 F1: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date.
Freenome, Inc.
Report date July 20, 2026 · Filed July 22, 2026
Section 16 reporting ended · disclosed 2026-07-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-07-20 transaction · row 1
1 source rowRow 1 · 2026-07-20 · Conversion · Acquired 30,000 · Balance 30,000 F1: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. |
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-20 · Conversion · Disposed 30,000 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. ("Old Freenome"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the "BCA"), on July 20, 2026 (the "Closing Date"), the Issuer consummated its business combination with Old Freenome (the "Business Combination"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis.
Prometheus Biosciences, Inc.
Report date June 16, 2023 · Filed June 16, 2023
Section 16 reporting ended · disclosed 2023-06-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 1
1 source rowRow 1 · 2023-06-16 · Disposition to issuer · Disposed 178,098 · Balance 0 F1: Includes 37,113 restricted stock units. F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2029-11-06 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-16 · Disposition to issuer · Disposed 161,105 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2030-05-04 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-16 · Disposition to issuer · Disposed 132,741 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2030-08-11 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2030-12-17 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-06-16 · Disposition to issuer · Disposed 481,725 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-16 · Disposition to issuer · Disposed 566,307 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.32 · Expires 2031-11-13 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-06-16 · Disposition to issuer · Disposed 290,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.56 · Expires 2032-05-19 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-06-16 · Disposition to issuer · Disposed 246,639 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $110.20 · Expires 2032-12-08 | Direct | 0 |
Reported balance
After 2023-06-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-06-16 · Disposition to issuer · Disposed 128,930 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3) F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 37,113 restricted stock units.
F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,.. (Continued in Footnote 3)
F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2023 Filed Feb 17, 2023 21:31 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | SaleCommon Stock | 25,000 | $119.87 | $2,996,750.00 |
DisclosureSEC source: 0001209191-23-010972 · doc4.xml · nonDerivative · entry 4 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,144 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:31 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Exercise / conversionCommon Stock | 25,000 | $3.70 | $92,500.00 |
DisclosureSEC source: 0001209191-23-010972 · doc4.xml · nonDerivative · entry 3 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:31 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-23-010972 · doc4.xml · derivative · entry 7 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,633 Underlying: Common Stock · 25,000 shares Expires 2029-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:31 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | SaleCommon Stock | 25,000 | $119.42 | $2,985,500.00 |
DisclosureSEC source: 0001209191-23-010972 · doc4.xml · nonDerivative · entry 2 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,144 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:31 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Exercise / conversionCommon Stock | 25,000 | $2.90 | $72,500.00 |
DisclosureSEC source: 0001209191-23-010972 · doc4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 20:39 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-23-004136 · doc4.xml · derivative · entry 3 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,633 Underlying: Common Stock · 25,000 shares Expires 2029-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person in April 2022. F3 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 20:39 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | SaleCommon Stock | 25,000 | $118.99 | $2,974,750.00 |
DisclosureSEC source: 0001209191-23-004136 · doc4.xml · nonDerivative · entry 2 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,144 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person in April 2022. F2 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 20:39 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Exercise / conversionCommon Stock | 25,000 | $2.90 | $72,500.00 |
DisclosureSEC source: 0001209191-23-004136 · doc4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person in April 2022. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 20:32 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantStock Options (Right to Buy) · Derivative | 128,930 | $0.00 Strike: $110.20 | $0.00 |
DisclosureSEC source: 0001209191-22-061088 · doc4.xml · derivative · entry 2 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,930 Underlying: Common Stock · 128,930 shares Expires 2032-12-08 F3 · derivative.exercise_date: 25% of the shares subject to the option will vest on December 9, 2023, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 20:32 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantCommon Stock | 37,113 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061088 · doc4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,144 F1 · kind: Award of restricted stock units ("RSUs") granted under the Issuer's 2021 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award will vest and settle with respect to twenty-five percent (25%) of the total number of RSUs on December 9, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service with the Issuer through each vest date. F2 · balance_after: Includes a total of 2,631 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 20, 2022 Filed May 20, 2022 19:11 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantStock Option (Right to Buy) · Derivative | 246,639 | $0.00 Strike: $29.56 | $0.00 |
DisclosureSEC source: 0001209191-22-031163 · doc4.xml · derivative · entry 1 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,639 Underlying: Common Stock · 246,639 shares Expires 2032-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the third anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 19:02 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,400 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-21-067992 · doc4.xml · derivative · entry 2 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,531 Underlying: Common Stock · 15,400 shares Expires 2029-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on September 9, 2020, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 19:02 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | Exercise / conversionCommon Stock | 15,400 | $2.90 | $44,660.00 |
DisclosureSEC source: 0001209191-21-067992 · doc4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2021 Filed Nov 16, 2021 21:03 UTC | Prometheus Biosciences, Inc. RXDX · Entity 112175 | GrantStock Option (Right to Buy) · Derivative | 290,000 | $0.00 Strike: $36.32 | $0.00 |
DisclosureSEC source: 0001209191-21-064933 · doc4.xml · derivative · entry 1 McKenna Mark C. · CIK 0001749623 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2031-11-13 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on November 14, 2022, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:15 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | SaleCommon Shares, No Par Value | 10,773 | $21.83 | $235,220.91 |
DisclosureSEC source: 0001127602-19-027163 · form4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,756 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.82 to $21.845 per share. The Reporting Person will provide to the Commission, the Issuer and any stockholder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range provided in this footnote. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 20:17 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 1,913 | $23.82 | $45,567.66 |
DisclosureSEC source: 0001127602-19-022856 · form4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,529 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| May 06, 2019 Filed May 8, 2019 20:16 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 746 | $23.51 | $17,538.46 |
DisclosureSEC source: 0001127602-19-017744 · form4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,442 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 20:38 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 974 | $23.56 | $22,947.44 |
DisclosureSEC source: 0001127602-19-011050 · form4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,188 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:13 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 44,290 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001127602-19-009255 · form4.xml · derivative · entry 2 McKenna Mark C. · CIK 0001749623 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,290 Underlying: Common Shares, No Par Value · 44,290 shares Expires 2029-02-27 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:13 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 15,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009255 · form4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,162 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:11 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 1,190 | $21.25 | $25,287.50 |
DisclosureSEC source: 0001127602-19-001767 · form4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,941 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.